A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer
NCT01472770
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
49
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
Gemcitabine + Capecitabine
Sponsor
Vejle Hospital